The DOI matches its Crossref record; the references it cites are not checked yet; 13 of the 134 sources its claims cite were checked for support.
Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications
Open accessAbstract
The spreading of antibiotic resistance is responsible annually for over 700,000 deaths worldwide, and the prevision is that this number will increase exponentially. The identification of new antimicrobial treatments is a challenge that requires scientists all over the world to collaborate. Developing new drugs is an extremely long and costly process, but it could be paralleled by drug repositioning. The latter aims at identifying new clinical targets of an “old” drug that has already been tested, approved, and even marketed. This approach is very intriguing as it could reduce costs and speed up approval timelines, since data from preclinical studies and on pharmacokinetics, pharmacodynamics, and toxicity are already available. Antidepressants and antipsychotics have been described to inhibit planktonic and sessile growth of different yeasts and bacteria. The main findings in the field are discussed in this critical review, along with the description of the possible microbial targets of these molecules. Considering their antimicrobial activity, the manuscript highlights important implications that the administration of antidepressants and antipsychotics may have on the gut microbiome.
Overview
CoChat Summary
TL;DR
This critical review summarizes evidence that antidepressants and antipsychotics have antimicrobial activity against bacteria, fungi, and some viruses, with *Candida albicans* as a common target, and discusses drug repositioning implications. It highlights possible mechanisms and argues that effects on the gut microbiome and microbial targets require further study before these drugs can be considered true antimicrobials.
Key findings
- Antimicrobial resistance causes over 700,000 deaths annually worldwide; new drug development can take up to 17 years, and discovery of new antibacterial agents has dropped by more than 50%, motivating drug repositioning.
- Antidepressants and antipsychotics inhibit planktonic and sessile growth of different yeasts and bacteria; sertraline is the most studied, active in some cases at 9 µM, tested on more than 20 microbes, and able to inhibit *C. albicans* virulence factors and biofilm while synergizing with fluconazole.
- Working concentrations are within the range of known antimicrobials (for *C. albicans*, fluconazole MIC90 is around 3 µM), and combinations with azoles or amphotericin B show fractional inhibitory index well below 0.5.
- Proposed mechanisms include inhibition of efflux pumps, disturbance of mitochondria, and disruption of membranes or lipid rafts; some TCAs and thioridazine resensitize MRSA to β-lactam, and phenelzine, desipramine, venlafaxine, bupropion, aripiprazole, and (S)citalopram inhibited gut commensals such as *Bifidobacterium animalis* and *Bacteroides fragilis*.
Methods
- Critical/perspective review based on bibliographic searches from May to August 2021 in PubMed, Elsevier’s Scopus, Web of Science Clarivate Analytics, and Google Scholar, using keyword combinations such as sertraline-antimicrobial, sertraline-repurposing, sertraline-fungi, and SSRIs-bacteria.
- The paper synthesizes in vitro and some in vivo studies in Table 1, listing drug class, microbial target, effective concentration, physiological effects, and references, then discusses proposed mechanisms and implications for gut ecology.
Limitations
- The paper states that examined reports do not include specific details on mechanism of action and molecular targets, that less is known about effects on bacteria, and that more studies are needed to identify microbial targets, gut microbiome effects after short or prolonged administration, active antimicrobial concentrations, topical use, and combination effects.
- The paper notes that almost all Table 1 papers report in vitro testing, with only some in vivo testing, and that clinical data on gut microbiota and serotonergic signaling remain very limited; studies in depressed patients often occurred during treatment, so more pre- and post-treatment microbiome data are needed.
- Evident from the text: as a narrative critical review, it does not report a systematic search protocol, risk-of-bias assessment, or meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
10 Valid · 3 Not valid · 81 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Taking fluoxetine lowers the risks of intubation and death by reducing the “cytokine storm” [29,30].”
§ Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications > 1. Introduction
What the sources say
- Partly supportedcites [29] Hoertel, N., Sánchez-Rico, M., Vernet, R., Beeker, N., Jannot, A.S., Neuraz, A., Salamanca, E., Paris, N., Daniel, C., and Gramfort, A. (2021). Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: Results from an observational study. Mol. Psychiatry, 1–14. sourceExperimental — accuracy not yet measured
The Study endpoint section reports that fluoxetine exposure was significantly associated with a lower risk of the composite outcome of intubation or death in hospitalized COVID-19 patients. The Discussion proposes preventing a cytokine storm as one possible mechanism for antidepressants generally, but does not establish that fluoxetine causes the lower risk or that it does so through this mechanism. Page numbers are unavailable in our copy. (LLM, conf=0.90)
- Partly supportedcites [30] Creeden, 2021, Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection, Biomed. Pharmacother. sourceExperimental — accuracy not yet measured
The Discussion says fluoxetine has the potential to reduce cytokine-storm severity and the risk of death in COVID-19, while the Conclusion says it may increase survival; neither section reports a demonstrated causal reduction. The Introduction cites an observational association between antidepressant use—not specifically fluoxetine—and lower risk of intubation or death. Thus the claim overstates both the certainty and the fluoxetine-specific evidence for intubation. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, this drug was able to inhibit the viral RNA and proteins of Coxsackievirus [66].”
§ Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications > 5. Possible Antimicrobial Activities of Antidepressants and Antipsychotics
What the sources say
- Supportedcites [66] Zuo, 2012, Fluoxetine is a potent inhibitor of coxsackievirus replication, Antimicrob. Agents Chemother. source
The Abstract states that fluoxetine and norfluoxetine 'markedly reduced the synthesis of viral RNA and protein' of coxsackievirus, and the Results (section 'Inhibition of viral RNA and viral protein accumulation by fluoxetine and norfluoxetine') report total abrogation of detectable CVB3 viral protein by immunoblotting and a >1,000-fold reduction in CVB3 RNA by RT-PCR. The Discussion confirms both compounds 'completely blocked viral protein synthesis' across multiple coxsackievirus B strains. The paraphrase matches the source, which frames this as reduced synthesis rather than direct virucidal activity (a point the claim does not misstate). (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Sertraline was initially demonstrated to be able to potentiate the action of azoles against cryptococcal microbes [60]; later, it was tested in a Phase II study [94] and a follow-up Phase III study in HIV patients infected by this fungus, but with no convincing results [95].”
§ Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications > 5. Possible Antimicrobial Activities of Antidepressants and Antipsychotics
What the sources say
- Supportedcites [94] Rhein, 2016, Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: An open-label dose-ranging study, Lancet Infect. Dis. source
The Methods (Study Design; page not provided) identify this as an open-label pilot study conducted in anticipation of a follow-up phase III trial. The Methods also report that it tested adjunctive sertraline in HIV-infected patients with cryptococcal meningitis. This source is cited as [94] for the phase II study; the sentence cites [95], not this paper, for the later trial and its unconvincing results. (LLM, conf=0.92)
- Not checked yetcites [95] 2018, Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: A single Mexican center experience, Infection source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Probiotics have been recently tested to re-establish a healthy microbial status, due to their ability to balance the dysbiosis created under the depressive state [117].”
§ Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications > 7. Implications of the Antimicrobial Activity of Antidepressants in Human Gut Ecology
What the sources say
- Partly supportedcites [117] Nikolova, V.L., Cleare, A.J., Young, A.H., and Stone, J.M. (2021). Updated Review and Meta-Analysis of Probiotics for the Treatment of Clinical Depression: Adjunctive vs. Stand-Alone Treatment. J. Clin. Med., 10. sourceExperimental — accuracy not yet measured
The Introduction describes gut dysbiosis in people with affective disorders and says probiotics are among the treatments targeting gut microbiota. The Discussion proposes that probiotics may restore microbial balance, but does not establish that they do so; the claim presents this proposed ability as established. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“| Paroxetine (third generation of selective serotonin reuptake inhibitors) | C. albicans, E. coli, A. baumanii | 110-282 µM (40-101 µg/mL) | Inhibits cell growth; promotes mitochondrial inhibits bacterial growth. depolarization and membrane damage in yeast, | [56,58,67-69] |”
§ Antimicrobial Properties of Antidepressants and Antipsychotics-Possibilities and Implications > •
What the sources say
- Not checked yetcites [56] Moraes, 2019, Insights on the anticandidal activity of non-antifungal drugs, J. Mycol. Med. source
- Partly supportedcites [58] Temel, 2020, Antifungal and antibiofilm activities of selective serotonin reuptake inhibitors alone and in combination with fluconazole, Turkish J. Pharm. Sci. sourceExperimental — accuracy not yet measured
The Minimum inhibitory concentrations of fluconazole and SSRIs section (Table 2, p. 670) shows that paroxetine inhibits growth of Candida fungi, with MICs of 64–512 µg/mL. It does not report bacterial growth inhibition or the claimed range of 110–282 µM (40–101 µg/mL). (LLM, conf=0.86)
- Not checked yetcites [67] Foletto, 2020, Repositioning of fluoxetine and paroxetine: Study of potential antibacterial activity and its combination with ciprofloxacin, Med. Chem. Res. source
- Partly supportedcites [68] Campos, 2017, In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates, Microb. Pathog. sourceExperimental — accuracy not yet measured
Table 1 reports that paroxetine inhibits growth of Candida yeasts, with MICs that include 40–100.8 µg/mL. It does not report inhibition of bacterial growth at 110–282 µM, so the bacterial part of the attributed claim is unsupported by this paper. (LLM, conf=0.88)
- Could not verifycites [69] Nobile, C.J., Ennis, C.L., Hartooni, N., Johnson, A.D., and Lohse, M.B. (2020). A selective serotonin reuptake inhibitor, a proton pump inhibitor, and two calcium channel blockers inhibit candida albicans biofilms. Microorganisms, 8. sourceExperimental — accuracy not yet measured
The Results (§3.2; page unavailable) report that paroxetine hydrochloride inhibited C. albicans biofilms at an MBIC of 50 µM, while its planktonic MIC was at least 200 µM. The Methods (§2.1; page unavailable) identify the assay organism as C. albicans. Our copy does not report bacterial growth inhibition by paroxetine at 110–282 µM (40–101 µg/mL). (LLM, conf=0.77)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
67 more claims · 2 with their cited sources checked
Create a free account to see all 114 claims and to verify the 121 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 16
Citations
The citation lists are queued
They are fetched later and appear here then.
References 120 · Cited by 54
Research works printed but not linked: 2
- Szarmach, 2017, Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy, Psychiatr. Danub., 29, S345
- Lang, 2012, Recent progress of acridine derivatives with antitumor activity, Prog. Chem., 24, 1497
Metadata
- Authors
- Caldara, M., & Marmiroli, N.
- Affiliations
- University of Parma (IT)
- Corresponding author
- Caldara, Marina
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2021-09-10
- Volume
- 14
- Issue
- 9
- Pages
- 915
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC8470654
- OpenAlex
- W3200385998
- Cited by
- 54
- References
- 120
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 12 · 2023: 10 · 2022: 7
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antimicrobial agents and applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- antidepressants, antipsychotic drugs, antimicrobial activity, drug repurposing, antibiotic resistance, gut microbiota, yeast growth inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications. https://app.cochat.ai/papers/10.3390/ph14090915
- The paper
- Caldara, M., & Marmiroli, N. (2021). Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications. Pharmaceuticals. https://doi.org/10.3390/ph14090915
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.